Cytek Biosciences, Inc. (CTKB)

In October 2025, Cytek Biosciences announced the expansion of its European presence with a new facility in Amsterdam. In November 2025, the Cytek® Muse® Micro Cell Analyzer won the BioTech Breakthrough Award for Drug Discovery Solution of the Year, and Cytek was recognized on TIME's 2026 list of America's Growth Leaders; insider trading activity and analyst price targets also occurred. In February 2026, Cytek Biosciences reported its Fourth Quarter and Full Year 2025 financial results, reporting Q4 revenue of $62.1 million and full-year revenue of $201.5 million, and participated in the TD Cowen 46th Annual Health Care Conference. In March 2026, Cytek Biosciences celebrated one year of operations at its Singapore facility. In April 2026, the stock price was $4.53, and the stock moved above its 50-day moving average.

Cytek Biosciences has indicated that its typical seasonal pattern for revenue is skewed towards the back half of the year. The overall flow cytometry market, in which Cytek operates, is projected to experience significant growth in the coming years, driven by factors such as advancements in technology, increasing adoption in clinical diagnostics, the rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine. The company's specific revenue seasonality leans towards stronger performance in the latter half of the fiscal year.

Cytek Biosciences, Inc. provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. Its core FSP instrument platform includes the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, and Cytek Aurora™ Evo systems, which are full spectrum flow cytometers. The company also offers the Cytek Orion™ reagent cocktail preparation system, Enhanced Small Particle™ (ESP™) detection technology, and flow cytometers and imaging products under the Amnis® and Guava® brands. In addition to instruments, Cytek provides reagents, software (such as SpectroFlo software), and services, positioning its offerings as an integrated suite of cell analysis solutions. While most of its products are for research use only, the Northern Lights-CLC system and certain reagents are available for clinical use in China and the European Union.

Headquartered in Fremont, California, Cytek Biosciences has a global presence with offices and distribution channels across the globe. The company has expanded its European operations, including the relocation and expansion of its European headquarters in Amsterdam, which now features an increased footprint and a dedicated customer service and training center. Cytek also has a significant presence in the Asia-Pacific region, including a facility in Singapore that celebrated one year of operations in March 2026. The company distributes its products through direct sales forces and support organizations in North America, Europe, China, and the Asia-Pacific regions, and through distributors or sales agents in Europe, Latin America, and the Middle East countries.

In November 2025, the Cytek® Muse® Micro Cell Analyzer was awarded the 2025 BioTech Breakthrough Award for Drug Discovery Solution of the Year. In November 2025, Cytek Biosciences was included in TIME's 2026 list of America's Growth Leaders, highlighting the company's sustained business expansion and the impact of its Full Spectrum Profiling™ (FSP®) flow cytometry platform.

Institutional investors hold a significant portion of Cytek Biosciences' shares, with 160 institutional owners holding a total of 82,300,826 shares, representing 60.91% of the company's shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Topline Capital Management, LLC, and others. Company co-founders Dr. Wenbin Jiang and Dr. Ming Yan hold significant insider stakes. Ra Capital Management LP is also listed as a large individual shareholder.